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The aim of this study was to compare the drug-resistance patterns of Mycobacterium tuberculosis strains among pulmonary 
tuberculosis patients, according to their HIV serostatus, in Burkina Faso. Tuberculosis (TB) patients were classified in new 
and previously treated cases by using a structured questionnaire. Susceptibility testing to isoniazid, streptomycin, 
rifampicin and ethambutol was done by the proportion method. Association between HIV-serostatus and drug-resistant TB 
was assessed with χ2 tests, and the statistical significance was set to P<0.05. Of 316 (249 new, 67 previously treated) patients 
included in the study, 68.7% were males and 28.8% were HIV-positive; females (36.4%) were more infected than males 
(25.3%), (P=0.04). The average age of the patients was 37.24±12.76 years [11-75years]. Most of the patients infected with HIV 
were aged from 15 to 44 years and were females, (P=0.01). In the new cases of TB, the difference between HIV-positive and 
HIV-negative patients was not statistically significant neither for the MDR-TB (P=0.40), nor for the resistant-TB to any drug 
(P=0.26). However, the difference was significant for the resistance to isoniazid and streptomycin alone (P=0.04). Among the 
previously treated patients, although there was more MDR-TB and more resistance to any drug in HIV-negative patients 
than among HIV-positive patients, these differences also were not statistically significant (P=0.54 and P=0.63, respectively). 
This study found no significant difference between TB/HIV-negative and TB/HIV-positive patients according to the 
resistance patterns to anti-TB medications, excepted the resistance to isoniazid in new cases and to isoniazid and 
streptomycin in all patients took globally. These results encourage the collaboration between the programs against TB and 
HIV to prevent rapid diffusion of drug-resistant TB and high mortality in patients living with HIV/AIDS as recommended 
by the World Health Organization. 
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INTRODUCTION  
Tuberculosis (TB) is one of the most important 
opportunistic infections in people living with the 
human immunodeficiency virus and AIDS 
(PLHIV/AIDS). The increase of TB cases worldwide 
was attested by the World Health Organization (1); 
every second, one new person in the world is 
infected with Mycobacterium tuberculosis and nearly 
1% of the world population is newly infected 
annually. Almost 9 million people develop the 
disease while 3.4 million die of it. Overall 
nowadays, one third of the world population is 
infected and 22 countries account for 80% of cases 
worldwide. Nearly 2 million annual cases of TB 
occur in sub-Saharan Africa (1, 2). Since 2009, this 
region is the most affected by the epidemic of HIV 
infection in the world. Despite the efforts, the 
epidemic is stable overall and the number of new 
infections continues to exceed the number of people 
put on antiretroviral treatment (3). The epidemic of 
AIDS contributes to worsen the impact of TB but the 
extent of the increase varies in different studies (4-
6). TB and HIV infection are in fact a complex co-
infection; the PLHIV/AIDS are 50 times more likely 
to develop TB during their lifetime than HIV-
negative patients since TB is an early manifestation 
of infection by HIV (5, 7). TB is the leading cause of 
death in people infected with HIV. Every 3 minutes, 
a person with HIV dies of TB worldwide. The 
negative relationship between TB bacilli resistant to 
antibiotics and HIV infection has been reported in 
some parts of the world. Given the poor adherence 
to TB treatment and the weakness of health systems, 
the growing epidemic of multidrug-resistant TB 
(MDR-TB) in HIV-positive patients in the world is a 
challenge that requires immediate action. 
PLHIV/AIDS are in fact more likely to be infected 
by mycobacteria including drug-resistant strains. In 
addition, HIV infection greatly increases the fatality 
rate of MDR-TB and ultra drug resistance (XDR) (8, 
9). Several countries have reported increasing rates 
of drug resistance, but in most of low-income 






In Burkina Faso, 33,437 new cases of TB including 
all forms, were diagnosed in 2007, with an incidence 
of 226 cases per 100 000 habitants. This represents 
60% of acid fast bacilli (AFB) smear-positive (10). 
Recent studies have revealed the prevalence of co-
infection with Mycobacterium tuberculosis and HIV to 
31.6% (11). Few studies have been devoted to 
assessing the resistance of M. tuberculosis in TB 
patients infected with HIV and it is only recently 
that research on drug-resistant TB began to take a 
reasonable size.  
The aim of this study was to compare the patterns 
of resistance to anti-TB drugs according to the HIV 
serostatus of the patients in Burkina Faso, a country 
where the prevalence of HIV infection is decreasing. 
 
PATIENTS AND METHODS  
Patients and study setting  
Between April 2005 and September 2006, 316 TB 
patients who had accepted to be tested for 
antibodies to HIV, were identified by smears sputa 
microscopic and cultures. They were included 
consecutively in two great public centers, “Centre 
National de Lutte Antituberculeuse” (CNLAT) in 
Ouagadougou, “Centre Regional de Lutte 
Antituberculeuse” (CRLAT) in Bobo-Dioulasso, and 
in two other centers, Dori Hospital Centre and 
Gorom-Gorom Medical Centre. The careful 
examination using a structured questionnaire was 
used to classify the patients into "new” and 
“previously treated” tuberculosis cases. The study 
was carried out under anonymous conditions and 
both Review Board of the University Hospital 
“CHU Yalgado Ouedraogo” and the National Ethics 
Committee approvals were obtained.  
 
General laboratory procedures 
TB was confirmed by culture; drug susceptibility 
testing (DST) of Mycobacterium tuberculosis complex 
(MTC) strains as well as HIV-serostatus testing were 
performed. The non-consenting patients, those with 
a history of TB treatment has failed to classify them 
as "never treated" or "already treated", those 
infected with non-tuberculous mycobacteria (NTM) 
and patients with bacilli with unknown 
bacteriological profile were not included in the 
study.  
 
Bacteriological investigations  
Standard procedures were used according to the 
practice in the country. AFB sputum microscopy, 
cultures, identification and first-line drugs 
susceptibility testing (DST) in complex M. 
tuberculosis strains were performed at the CNLAT 
laboratory. After microscopic analysis, specimens 
were sent by other Centres to CNLAT laboratory for 
cultures and DST. They were homogenized and 
decontaminated using the method of Petroff. The 
pellet was then inoculated into four media of 
Lowenstein-Jensen (LJ), including one with 0.4% 
sodium pyruvate (LJ+Pyruvate) and another one 
with thiophene-2-carboxylic acid (LJ+TCH). The 
tubes were incubated and examined after 3 days 
and then weekly during three months. The isolates 
were identified by acid-fast stain, growth rate, 
morphology, resistance to TCH, growth on 
LJ+Pyruvate and reactions to usual biochemistry 
tests (niacin, nitrate reductase, catalase activity at 
22°C and 70°C). Drug susceptibility testing (DST) 
was performed by a simplified version of the 
proportion method described elsewhere (12, 13). 
The following drugs have been tested: isoniazid 
(0.2µg/ml), streptomycin (4µg/ml), rifampicin 
(40µg/ml), ethambutol (2µg/ml). The M. 
tuberculosis H37 ATCC 27294 strain was used for the 
quality control in DST. Proficiency testing for 
culture and identification were done in 
collaboration with the National Reference Center for 
Mycobacteria in Borstel (Parkallee Borstel, 
Germany): 10 strains of M. tuberculosis Complex 
strains were used for this control. 
 
HIV testing 
A blood sample was collected for HIV testing after 
counselling and consent had been obtained from the 
patients. All patients were reassured of the 
confidentiality of their results. Two rapid tests were 
performed according to the UNAIDS/WHO 
recommendations (14): the blood sample was first 
tested using the Determine™HIV-1/2 (Inverness 
Medical, Courbevoie Cedex, France). Afterwards, 
the positive samples were tested with 
ImmunoComb®II BiSpot HIV-1&2 (PBS Orgenics, 
Courbevoie Cedex, France) to discriminate among 
HIV-1, HIV-2, and dual-reactive. Any sample that 




The standard chi-square tests (χ2) were used to 
assess statistical relationships between HIV-
serostatus and drug-resistant TB by using SPSS 15.0 
(SPSS Inc., Paris, France). Linear-by-linear 
association or likelihood ratio was used to interpret 





This study did not include patients with negative or 
uninterpretable cultures, unknown HIV-serostatus 
in non-tested patients, or infected by 
nontuberculous mycobacteria. Thus, the population 
of study comprised 316 patients infected with 
strains of M. tuberculosis complex (MTC) and having 
DST results. Of the 316 patients examined, 249 were 
new cases and 67 were previously treated patients. 
In the latter group of patients, 14 (20.9%) were 
relapses, 8 (11.9%) returned to treatment after 
default and 45 (67.2%) were failures. These failures 
included 31 chronic cases and 14 failures in the 5th 
and 7/8th months. Among the 316 patients, 217 
(68.7%) were male and 99 (31.3%) female. The 





years]; 25 (14.9) patients were less than 25 years old, 
190 (60.1%) were aged from 11 to 44 years and 79 
(25%) were more than 44 years old (Table 1).  
 
HIV serostatus of the patients 
HIV-serostatus of the patients according to their sex 
and group age is shown in table 1. Of 316 patients, 
91 (28.8%) were HIV-positive, including 78 of the 
249 new cases and 13 of the 67 previously treated 
patients. Globally, female patients (36.4%) were 
more infected by HIV than male (25.3%), and this 
difference according to genders was statistically 
significant (P=0.04). The rate of HIV infection was 
higher in patients being less than 44 years than in 




TABLE 1 HIV SEROSTATUS OF PATIENTS ACCORDING TO THEIR GENDER AND AGE GROUPS 
 



















≤25 4 (16.7) 24   0  6   4 (13.3) 30   
25-44 31(31) 100  0.33 4 (14.8) 27  0.34 35 (27.6) 127  0.223 
>44 14(28.6) 49   2 (18.2) 11   16 (26.7) 60   





≤25 3 (21.4) 14   0  3   3 (17.6) 17   
25-44 24 (47.1) 51  0.06 7 (58.3) 12   31 (49.2)  0.001 
>44 2 (18.2) 11   0  8   2 (10.5) 19   
Total 29 (38.2) 76   7 (30.4) 23   36 (36.4) 99   
 
Drug resistance according to HIV-serostatus 
The drug-resistance rate in TB patients according to 
their HIV-serostatus is shown in Table 2. Seventy-
eight (31.3%) patients among the new cases were 
HIV-positive: among them, 0.8% was MDR versus 
2% in TB/VIH-negative (P=0.40). Ten (4%) TB/HIV-
positive and 17 (6.8%) TB/HIV-negative were 
resistant to any drug (P=0.26); 6 (2.4%) TB patients 
HIV-positive and 4 (1.6%) HIV negative were 
resistant to isoniazid and streptomycin alone; the 
rates of resistance to isoniazid was statistically 
significant (P=0.046).  
Thirteen (19.4%) of the 67 patients previously 
treated were HIV-positive. There was more MDR-
TB in HIV-negative patients (n=30; 44.8%) than in 
HIV-positive patients (n=6; 8.9%), and this 
difference was not statistically significant (P=0.54). 
Eight (11.9%) TB/HIV-negative were resistant to all 
or any drug versus 37 (55.2%) in HIV-negative 
patients (P=0.63).  
According to genders, 4.6% of male and 8.1% of 
female, all HIV-positive, were resistant to any drug 
(P=0.27 and P=0.85, respectively).  
 
DISCUSSION 
According to the UNAIDS’ report on the global 
HIV/AIDS epidemic in 2007, women were more 
infected than men: 61% of adults living with HIV in 
sub-Saharan Africa were women, while this rate 
was 58% in 2004 and 37% in 2001(15).  In this study 
realized in Burkina Faso, females TB patients also 
were more infected than males, particularly those 
aged from 15 to 44 years old. 
Concerning the DST results in Table 1, the most 
notable results and most disturbing are the high 
resistance to any anti-TB and multidrug resistance 
(MDR) observed in previously treated cases, 
although the resistance rates were not significantly 
different in both groups of HIV-positive and HIV-
negative. The resistance in HIV-positive new cases 
is lower than in HIV-negative patients. The high 
rates of resistance to INH and streptomycin STM are 
frequent within the strains of MTC. These strains 
were subjected for a long time to the pressure of 
antibiotics, what resulted in a more important 
resistance to INH and STM (16). In Burkina Faso, 
the combinations of anti-TB drugs include these 
antibiotics; the health workers have to remind 
themselves that 10% of the TB patients are 
spontaneously resistant to INH. As it is retained in 
standard treatments, patients and health workers 
must take greater control of all treatments started to 
avoid the maximum loss of generators and irregular 
treatment resistance. Resistance to streptomycin 
was also high but this drug is replaced in the second 
phase by ethambutol. In this study, the resistance 
rate to anti-TB drugs in HIV-negative and HIV-
positive patients was not statistically different 
according to genders and age ranges, suggesting 
that the epidemiology of resistance at the 
phenotypic level in West Africa is similar. With or 
without HIV, the treatment success of patients with 
MDR tuberculosis is lower than that of drug-
susceptible cases, but nevertheless it reached 70% 
(17).  
 
Although the rates of TB/HIV co-infection and 
resistance strains to anti-TB were high in our 
patients (28.8%), MDR-TB was not significantly 





results of other African studies (18-20). It is possible 
that many cases are not detected in patients with 
HIV because all AFB-positive identified patients 
were not included in the study; more particularly 
those who had refused HIV serological testing, 
which is always done in patients who accept it after 
their counselling. The TB patients included in the 
study were not under antiretroviral treatment when 
they had been diagnosed as HIV-positive. Contrary 
to our results, those obtained in industrialized 
countries had found a significant association 
between HIV infection and MDR-TB (21-24). The 
association between HIV infection and drug-
resistant tuberculosis is complex and multifaceted 
(25, 26). HIV co-infection in TB patients is not 
believed to increase the rate at which spontaneous 
resistance-conferring mutations occur. However, it 
might increase the number of mutants that arise 
overall by enlarging the pool of individuals with 
active tuberculosis disease (27).  
 
TABLE 2: COMPARISON OF TB PATIENTS ACCORDING TO HIV SEROSTATUS AND THE RESISTANCE TO FIRST-
LINE ANTI-TB THERAPY 
 



















To all drugs  10 (4) 29 (11.6) - 8 (11.9) 45(67) - 18 (5.7) 74 (23.4) - 
To each drug          
H 8 (3.2) 20 (8) 0.39 8 (11.9) 37(55.2) 0.63 16 (5.1) 65 (20.6) 0.39 
R 1 (0.4) 7 (2.8) 0.29 6 (8.9) 30(44.8) 0.54 7 (2.2) 43 (13.6) 0.04 
E 1 (0.4) 7 (2.8) 0.29 6 (8.9) 30(44.8) 0.54 7 (2.2) 43 (13.6) 0.04 
S 4 (1.6) 13 (5.2) 0.98 7 (10.4) 24(35.8) 0.54 11 (3.5) 44 (14) 0.56 
Monoresistance           
H only 6 (2.4) 12 (4.8) 0.09 0 2(2.9) - 6 (1.9) 12 (3.8) 0.99 
R only 0 0 - 0 0 - 0 0 - 
E only 0 1 (0.4) - 0 0 - 0 1 (0.3) - 
S only 2 (0.8) 6 (2.4) 0.90 0 0 - 2 (0.6) 6 (1.9) 0.797 
Total  8 (3.2) 19 (7.6) 0.14 0 2(2.9) - 8 (2.5) 19 (6) 0.18 
MDR           
RH 0 2 (0.8) - 0 5 (7.5)  0 7 (2.2) - 
RHE 0 0 - 1 (1.5) 4 (5.9) 0.53 1 (0.3) 4 (1.3) 0.80 
RHS 0 0 - 0 0 - 0 0 - 
RHES 1 (0.4) 4 (1.6) 0.94 5 (7.5) 27(40.3) 0.50 6 (1.6) 31 (9.8) 0.13 
Total 1 (0.4) 6 (2.4) 0.4 6 (8.9) 36(53.7) 0.54 7 (2.2) 42 (13.3) 0.05 
Other patterns           
HE 0 2 (0.8) - 0 3 (4.5) - 0 5 (1.6) - 
HS 1 (0.4) 2 (0.8) 0.58 2 (2.9) 2 (2.9) - 3 (0.9) 4 (1.3) 0.040 
HSE 0 0 - 0 2 (2.9) - 0 2 (0.6) - 
RE 0 0 - 0 0 - 0 0 - 
RS 0  - 0 0 - 0  - 
RES 0 0 - 0 0 - 0 0 - 
ES 0 0 - 0 0 - 0 0 - 
Total  1 (0.4) 4  (1.6)  2 (2.9) 7 (10.4)  3 (0.9) 11(3.9)  
Resistance to          
1 drug 8 (3.2) 19 (7.6)  0 2 (2.9)  8 (2.5) 21 (6.6)  
2 drugs 1 (0.4) 6 (2.4)  2 (2.9) 10(14.9)  3 (0.9) 16 (5.1)  
3 drugs 0 0  1 (1.5) 6 (8.9)  1 (0.3) 6 (1.9)  
4 drugs 1 (0.4) 4 (1.6)  5 (7.5) 27(40.3)  6 (1.6) 31 (9.8)  
Total  10 (4) 29 (11.6) 0.26 8 (11.9) 45(67) 0.63 18 (5.7) 74 (23.4) 0.60 
 
H: isoniazid; R: rifampicin; E: ethambutol; S: streptomycin; MDR: multidrug-resistance; 
 
If immunosuppression is not very advanced, then 
the response to anti-TB treatment is usually similar 
in HIV-negative and HIV-positive patients, whereas 
HIV-positive patients have greater risk of suffering 
from drug toxicity and to die during the treatment 
(20, 28). This is well illustrated by the study 
conducted in KwaZulu-Natal in South Africa (29). 
The possible association between HIV and drug-
resistant MTC strains can be mainly explained by 
the fact that antiretroviral treatment could interfere 
with anti-TB drugs and make them less effective, or 
lead to resistance to these drugs (30). Patients with 
HIV-associated TB could have diminished 
adherence to treatment due to increased pill burden,  
 
 
overlapping toxic effects (31, 32). There is also the 
problem of malabsorption; therefore, they are prone 
to having subtherapeutic concentrations of anti-TB 
drugs (33).  
Often there is a dilemma when the treatment of 
TB/HIV-positive cases was not well codified: treat 
TB first or treat TB and HIV together, knowing that 
some antiretroviral drugs interfere with TB drugs 
(34). The protease inhibitors and non-nucleoside 
reverse transcriptase inhibitors are known to 
interact with rifampicin, a drug included in many 






In this work in Burkina Faso, the HIV testing was 
done during the study without knowledge on the 
patients’ serostutus before. Moreover, it was 
possible that HIV-positive patients and those 
having drug-resistant TB shared similar risk factors, 
such as the environmental conditions. Indeed, many 
outbreaks of drug-resistant TB were triggered in 
areas where relatively large numbers of HIV 
infected people were in close contact with each 
other, such as hospitals or prisons. However, 
information regarding the transmission of 
tuberculosis in these settings can be used to predict 
the spread of drug resistant tuberculosis in the 
general population. HIV infection and TB form a 
lethal combination when the degree of 
immunosuppression is advanced (5, 35). Studies of 
outbreaks in the early 1990s could show that 
patients with the acquired immunodeficiency 
syndrome (AIDS) and multidrug-resistant 
tuberculosis had a median survival of 4 to 16 weeks 
(36, 37).  
This study had not found a significant difference 
between TB/HIV-negative and TB/HIV-positive 
patients according to the resistance patterns to anti-
TB medications, excepted the resistance to INH in 
new cases and to INH and STM in all patients took 
globally. Indeed HIV infection increases TB 
epidemiology, but it cannot be responsible for the 
MDR-TB resurgence. Other serious factors may be 
implicated.  
To reduce the number of people with this dual 
infection, it is important to diagnosis contagious 
pulmonary TB patients early and to prevent 
transmission in the places where infected people are 
in close contact with each other, such as hospitals 
and prisons. Collaboration between the better and 
stronger programs against TB and HIV is needed to 
prevent rapid transmission of drug-resistant 
tuberculosis and high mortality in communities 
heavily affected by HIV. To this end, the WHO has 
recommended expanding the scope of collaborative 
TB/HIV (10).  
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